Oncology News | pharmaphorum

News

A drug at the heart of Johnson & Johnson's $3bn takeover of Halda has been shown to be "highly active" in a first-in-human prostate cancer trial.

News

BMS and SystImmune's EGFRxHER3 bispecific ADC iza-bren has scored in another phase 3 trial, boosting its credentials as a future blockbuster.

News

Two drugs hoping to muscle in on Amgen's first-to-market DLL3-targeting drug Imdelltra – from Zai Lab and Ideaya – have new trial readouts at ESMO.

News

AstraZeneca and Daiichi Sankyo's Enhertu failed to show efficacy as neoadjuvant therapy for early-stage HER2-low breast cancer in the TALENT trial.

News

Takeda and Innovent's CLDN18.2-targeting ADC, arcotatug tavatecan, will be filed in Japan on the back of positive survival data in gastric cancer.

News

A study of RevMed's Rasonque with Tango's vopimetostat has raised hopes of a new combination therapy for aggressive pancreatic cancer.